AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27935076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 24588277 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ointment (Aquaphor Original Emollient)
Number of subjects: 197
Study 24588277 — intervention group
Group type: COMPARATOR
Intervention: Routine skin care
Number of subjects: 197
Study 23164480 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone 7.5mg once daily
Number of subjects: 32
Study 23164480 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone 30mg once daily
Number of subjects: 32
Study 23164480 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 21107748 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g/l propofol (n = 64)
Number of subjects: 103
Study 21107748 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (placebo) (n = 39)
Number of subjects: 103
Study 19273450 — intervention group
Group type: EXPERIMENTAL
Intervention: High MBL2 expression genotypes (O/O, A/O, A/A)
Number of subjects: 158
Study 16893569 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally depressed subjects
Number of subjects: 206
Study 16893569 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed subjects
Number of subjects: 206
Study 15356807 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted physiologic diet
Number of subjects: 105
Study 15356807 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted diet
Number of subjects: 105
Study 11397886 — intervention group
Group type: EXPERIMENTAL
Intervention: Children treated for ALL
Number of subjects: 68
Study 11397886 — intervention group
Group type: COMPARATOR
Intervention: Healthy British children (comparison group)
Number of subjects: 68
Study 9438318 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC (20 mg omeprazole, 750 mg amoxicillin, and 250 mg clarithromycin, twice daily for 10 days)
Number of subjects: 61
Study 9438318 — intervention group
Group type: COMPARATOR
Intervention: BTC (240 mg bismuth subcitrate, 750 mg oxytetracycline, and 250 mg clarithromycin, twice daily for 10 days)
Number of subjects: 61
Study 8483424 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 implants, each containing 12 mg oestradiol valerate (E2V)
Number of subjects: 10
Study 8483424 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 implants, each containing 27 mg oestradiol benzoate (E2B)
Number of subjects: 10
Study 3717960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of THP, 5-Fluorouracil and cyclophosphamide (Group A)
Number of subjects: 64
Study 3717960 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin, 5-Fluorouracil and cyclophosphamide (Group B)
Number of subjects: 64
Study 29415523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation benefit topics and imagery types (DCE 1)
Number of subjects: 1000
Study 29415523 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages with tips to improve cessation success and imagery types (DCE 2)
Number of subjects: 1000
Study 29415523 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive health benefits of cessation topics and imagery types (DCE 3)
Number of subjects: 1000
Study 27768984 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback (BF)
Number of subjects: 84
Study 27768984 — intervention group
Group type: EXPERIMENTAL
Intervention: Active relaxation
Number of subjects: 84
Study 27768984 — intervention group
Group type: COMPARATOR
Intervention: Waiting control condition
Number of subjects: 84
Study 25219128 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 133
Study 25219128 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-needling
Number of subjects: 133
Study 25219128 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint
Number of subjects: 133
Study 21809090 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV + RES
Number of subjects: 29
Study 21809090 — intervention group
Group type: COMPARATOR
Intervention: PL + RES
Number of subjects: 29
Study 21250568 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with 5% d‐limonene combined with Perlite whitening formulation
Number of subjects: 408
Study 21250568 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with 5% d‐limonene alone (negative formulation)
Number of subjects: 408
Study 21250568 — intervention group
Group type: COMPARATOR
Intervention: Positive control with perlite whitening formulation
Number of subjects: 408
Study 21250568 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 408
Study 17943257 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of TNF inhibitors (etanercept, infliximab, adalimumab) plus methotrexate (MTX)
Number of subjects: 0
Study 17943257 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 0
Study 17943257 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 17943257 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 17943257 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 17943257 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-blocking agents (etanercept, adalimumab, infliximab)
Number of subjects: 0
Study 15743421 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil (TF)
Number of subjects: 79
Study 15743421 — intervention group
Group type: COMPARATOR
Intervention: Lateral Condensation (LC)
Number of subjects: 79
Study 15743421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TF and LC
Number of subjects: 79
Study 12787302 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 86
Study 12787302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 11764116 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser energy at 240 mJ
Number of subjects: 60
Study 11764116 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser energy at 200 mJ
Number of subjects: 60
Study 11764116 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser energy at 300 mJ with 100 mJ finish
Number of subjects: 60
Study 11764116 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional diamond bur)
Number of subjects: 60
Study 8723581 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (100 IU/kg s.c. on days -30, -23, -16, and -9 prior to surgery) with oral iron supplementation
Number of subjects: 62
Study 8723581 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (200 IU/kg s.c. on days -30, -23, -16, and -9 prior to surgery) with oral iron supplementation
Number of subjects: 62
Study 8723581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 1517652 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen 5 L/min delivered by mask
Number of subjects: 1
Study 1517652 — intervention group
Group type: COMPARATOR
Intervention: Air 5 L/min delivered by mask
Number of subjects: 1
Study 6367246 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg beta-methyl digoxin
Number of subjects: 45
Study 6367246 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 mg beta-methyl digoxin
Number of subjects: 45
Study 6367246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31508878 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dutasteride initiation
Number of subjects: 1206
Study 31508878 — intervention group
Group type: COMPARATOR
Intervention: Late initiation
Number of subjects: 1206
Study 31508878 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation
Number of subjects: 1206
Study 30814213 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 177
Study 30814213 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort (physician discretion)
Number of subjects: 177
Study 26660956 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic prophylactic inguinal lymphadenectomy with saphenous vein sparing
Number of subjects: 23
Study 26660956 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic prophylactic inguinal lymphadenectomy with saphenous vein ligated
Number of subjects: 23
Study 25223378 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 1 mg
Number of subjects: 40
Study 25223378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22906144 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture treatment
Number of subjects: 33
Study 22906144 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 33
Study 20813500 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of deproteinized bovine bone (DBB) and autogenous cancellous bone graft (1:1 by volume)
Number of subjects: 30
Study 20813500 — intervention group
Group type: COMPARATOR
Intervention: Autogenous cancellous bone graft harvested from the anterior iliac crests
Number of subjects: 30
Study 16547082 — intervention group
Group type: COMPARATOR
Intervention: Standard dose oral amoxicillin (45 mg/kg/day)
Number of subjects: 876
Study 16547082 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose oral amoxicillin (90 mg/kg/day)
Number of subjects: 876
Study 17430101 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody therapies targeting tumor and/or tumor micro-environment in combination with gemcitabine
Number of subjects: 0
Study 17430101 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus erlotinib (epidermal growth factor receptor tyrosine kinase inhibitor)
Number of subjects: 0
Study 12796517 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drug (AED) monotherapy
Number of subjects: 0
Study 12796517 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient conversion to monotherapy
Number of subjects: 0
Study 12796517 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical conversion to monotherapy
Number of subjects: 0
Study 10976984 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 0
Study 10976984 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic treatment for osteoporosis
Number of subjects: 0
Study 8879780 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B deoxycholate in 5% dextrose (0.7 mg/[kg.d] for 14 days, then 1 mg/kg every other day for 28 days)
Number of subjects: 90
Study 8879780 — intervention group
Group type: COMPARATOR
Intervention: Intralipid/amphotericin B (1 mg/[kg.d] for 14 days, then 1.5 mg/kg every other day for 28 days)
Number of subjects: 90
Study 8879780 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 1647829 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened cytomegalovirus (CMV) seronegative blood products
Number of subjects: 125
Study 1647829 — intervention group
Group type: COMPARATOR
Intervention: Unscreened blood products
Number of subjects: 125
Study 1647829 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened blood products
Number of subjects: 125
Study 6866306 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium heparin prophylaxis (5000 I.U. s.c. every 8 hr)
Number of subjects: 0
Study 30894141 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume online hemodiafiltration (HDF) for 6 months
Number of subjects: 0
Study 30894141 — intervention group
Group type: COMPARATOR
Intervention: High-flux hemodialysis (HD)
Number of subjects: 0
Study 28364497 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Sleep (HS; 10 hours in bed)
Number of subjects: 87
Study 28364497 — intervention group
Group type: COMPARATOR
Intervention: Short Sleep (SS; 6.5 hours in bed)
Number of subjects: 87
Study 26542697 — intervention group
Group type: EXPERIMENTAL
Intervention: Central video-based adjudication of modified Rankin scale (mRS)
Number of subjects: 226
Study 26542697 — intervention group
Group type: COMPARATOR
Intervention: Central phone-based adjudication of modified Rankin scale (mRS)
Number of subjects: 226
Study 26542697 — intervention group
Group type: COMPARATOR
Intervention: Local evaluation of modified Rankin scale (mRS)
Number of subjects: 226
Study 26542697 — intervention group
Group type: EXPERIMENTAL
Intervention: Final infarct volume correlation with mRS
Number of subjects: 226
Study 22626835 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supplementation of selenium and coenzyme Q10
Number of subjects: 443
Study 22626835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 21208780 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nut consumption providing approximately 290 μg of Se a day for 8 weeks
Number of subjects: 37
Study 19681809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg
Number of subjects: 451
Study 19681809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 90 mg
Number of subjects: 451
Study 19681809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 17645378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole 300 mg in a single dose per week for 2 weeks
Number of subjects: 63
Study 17645378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 17645378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole 300 mg
Number of subjects: 63
Study 14722779 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (240 days in a 100‐m(3) chamber)
Number of subjects: 8
Study 14722779 — intervention group
Group type: COMPARATOR
Intervention: Group II (110 days in a 200‐m(3) module)
Number of subjects: 8
Study 14722779 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I and Group II
Number of subjects: 8
Study 11394896 — intervention group
Group type: EXPERIMENTAL
Intervention: Glu298Asp polymorphism in the eNOS gene
Number of subjects: 119
Study 9323528 — intervention group
Group type: EXPERIMENTAL
Intervention: One hemp seed bar
Number of subjects: 0
Study 9323528 — intervention group
Group type: EXPERIMENTAL
Intervention: Two hemp seed bars
Number of subjects: 0
Study 9323528 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cookies made from hemp seed flour and butter
Number of subjects: 0
Study 9323528 — intervention group
Group type: COMPARATOR
Intervention: Hemp seeds (used in foodstuffs)
Number of subjects: 0
Study 8355864 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.125 mg intravenously after induction of anesthesia
Number of subjects: 20
Study 8355864 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine group
Number of subjects: 20
Study 8355864 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin infusion (control)
Number of subjects: 20
Study 2452254 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine 3 g/day
Number of subjects: 63
Study 2452254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 29664714 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Everolimus
Number of subjects: 131
Study 29664714 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant alone (Placebo)
Number of subjects: 131
Study 27793208 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI group
Number of subjects: 20
Study 27793208 — intervention group
Group type: COMPARATOR
Intervention: Control group (PER-operative)
Number of subjects: 20
Study 24029392 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire FR device
Number of subjects: 144
Study 24029392 — intervention group
Group type: COMPARATOR
Intervention: Merci device
Number of subjects: 144
Study 23126349 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 320 mg ± hydrochlorothiazide (HCTZ)
Number of subjects: 125
Study 23126349 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine 10 mg ± HCTZ
Number of subjects: 125
Study 23126349 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 125
Study 19959398 — intervention group
Group type: EXPERIMENTAL
Intervention: ParkinsonNet care (n=358)
Number of subjects: 699
Study 19959398 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=341)
Number of subjects: 699
Study 18649766 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (20 microg) and radix Salviae miliorrhazae (40 ml) intravenously once a day for 2 weeks
Number of subjects: 76
Study 18649766 — intervention group
Group type: COMPARATOR
Intervention: Enteric coated aspirin 3 times a day for 2 weeks and radix Salviae miliorrhazae (dropping pill)
Number of subjects: 76
Study 17159027 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine 125 brachytherapy
Number of subjects: 1317
Study 17159027 — intervention group
Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 1317
Study 12714128 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 705
Study 12714128 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 705
Study 11188531 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8958487 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 2 micrograms mL‐1 + Clonidine 3 micrograms mL‐1 with basal infusion (group SC+)
Number of subjects: 60
Study 8958487 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 2 micrograms mL‐1 + Clonidine 3 micrograms mL‐1 without basal infusion (group SC)
Number of subjects: 60
Study 8958487 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 2 micrograms mL‐1 with basal infusion (group S+)
Number of subjects: 60
Study 8958487 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 2 micrograms mL‐1 without basal infusion (group S)
Number of subjects: 60
Study 1558400 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT treatment
Number of subjects: 53
Study 1558400 — intervention group
Group type: COMPARATOR
Intervention: Intravesical adriamycin instillation
Number of subjects: 53
Study 3847417 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient cardiac patient education program consisting of five daily 1-hour classes
Number of subjects: 342
Study 3847417 — intervention group
Group type: COMPARATOR
Intervention: Posttest assessment only (Control group)
Number of subjects: 342
Study 3847417 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation indicators
Number of subjects: 342
Study 31945074 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily training interval
Number of subjects: 475
Study 31945074 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly training interval
Number of subjects: 475
Study 31945074 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly training interval
Number of subjects: 475
Study 31945074 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly training interval
Number of subjects: 475
Study 30364572 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-practices hearing intervention
Number of subjects: 850
Study 30364572 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 850
Study 28526552 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral intraocular lens (IOL) implantation with targeted postoperative refractive error of +8 diopters (D) for infants 28 to <48 days of age.
Number of subjects: 57
Study 28526552 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral intraocular lens (IOL) implantation with targeted postoperative refractive error of +6 D for infants 48-210 days of age.
Number of subjects: 57
Study 28526552 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with glaucoma in the treated eye (n=9).
Number of subjects: 57
Study 26631058 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (3.36 g daily for 3 months)
Number of subjects: 62
Study 26631058 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched)
Number of subjects: 62
Study 23769265 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrust Manipulation (TM)
Number of subjects: 49
Study 23769265 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Thrust Manipulation (NTM)
Number of subjects: 49
Study 23769265 — intervention group
Group type: COMPARATOR
Intervention: Age stratification (>70 years)
Number of subjects: 49
Study 21962063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg three times daily
Number of subjects: 62
Study 21962063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 21962063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 62
Study 18945586 — intervention group
Group type: EXPERIMENTAL
Intervention: Large font size (79.3%)
Number of subjects: 650
Study 18945586 — intervention group
Group type: EXPERIMENTAL
Intervention: Thicker paper (3.2%)
Number of subjects: 650
Study 18945586 — intervention group
Group type: COMPARATOR
Intervention: Small font size (75.2%)
Number of subjects: 650
Study 18945586 — intervention group
Group type: COMPARATOR
Intervention: Thinner paper (7.1%)
Number of subjects: 650
Study 15979245 — intervention group
Group type: EXPERIMENTAL
Intervention: ALERT Plus condition (basic curriculum with booster lessons added for 9th and 10th grades)
Number of subjects: 45
Study 15979245 — intervention group
Group type: EXPERIMENTAL
Intervention: ALERT condition (basic prevention curriculum delivered in 7th and 8th grades)
Number of subjects: 45
Study 15979245 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 45
Study 12850618 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve stimulation therapy
Number of subjects: 230
Study 12850618 — intervention group
Group type: COMPARATOR
Intervention: Control (nonstimulating placebo device)
Number of subjects: 230
Study 10372629 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanate acid treatment (group A)
Number of subjects: 100
Study 10372629 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group B)
Number of subjects: 100
Study 9101989 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic mediastinal lymphadenectomy
Number of subjects: 0
Study 9101989 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic adjuvant therapy
Number of subjects: 0
Study 9101989 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocytochemical techniques
Number of subjects: 0
Study 1892190 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin treatment (3 times daily for 7 days)
Number of subjects: 65
Study 1892190 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin treatment
Number of subjects: 65